Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $36.04 USD
Change Today +0.63 / 1.78%
Volume 158.1K
ANIK On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

anika therapeutics inc (ANIK) Snapshot

Open
$34.99
Previous Close
$35.41
Day High
$36.24
Day Low
$34.55
52 Week High
02/25/15 - $45.35
52 Week Low
04/29/15 - $31.36
Market Cap
527.3M
Average Volume 10 Days
172.9K
EPS TTM
$1.65
Shares Outstanding
14.6M
EX-Date
--
P/E TM
21.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for ANIKA THERAPEUTICS INC (ANIK)

Related News

No related news articles were found.

anika therapeutics inc (ANIK) Related Businessweek News

No Related Businessweek News Found

anika therapeutics inc (ANIK) Details

Anika Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair in the United States, Europe, and internationally. The company’s products are based on hyaluronic acid (HA), a naturally occurring biocompatible polymer found in the body. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, and MONOVISC for the treatment of osteoarthritis of the knee; Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; Hyalonect, a woven gauze used as a graft wrap; Hyaloss used to mix blood/bone grafts to form a paste for bone regeneration; and Hyaloglide, an ACP gel used in tenolysis treatment. The company’s dermal products include wound care products that comprise Hyalomatrix and Hyalofill, for treatment of complex wounds, such as burns and ulcers; Hyalograft 3D and Laserskin scaffolds for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise Hyalobarrier, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product for the prevention of spinal post-surgical adhesions; Merogel, a woven fleece nasal packin; and Merogel Injectable, a viscous hydrogel. The company’s ophthalmic products include STAARVISC-II, Optivisc, AnikaVisc, and NUVISC that are injectable HA products used as viscoelastic agents in ophthalmic surgical procedures, including cataract extraction and intraocular lens implantation. Its veterinary product comprise HYVISC, an injectable HA product used for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. markets its products through a network of distributors. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

105 Employees
Last Reported Date: 03/13/15
Founded in 1983

anika therapeutics inc (ANIK) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $998.8K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $459.0K
Chief Operating Officer
Total Annual Compensation: --
Chief Technology & Strategy Officer
Total Annual Compensation: $43.4K
Compensation as of Fiscal Year 2014.

anika therapeutics inc (ANIK) Key Developments

Anika Therapeutics Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Anika Therapeutics Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of USD 22,903,561 compared to USD 26,274,660 a year ago. Income from operations was USD 12,428,688 compared to USD 15,202,713 a year ago. Income before income taxes was USD 12,452,595 compared to USD 15,208,648 a year ago. Net income was USD 7,819,557 compared to USD 9,302,350 a year ago. Diluted net income per share was USD 0.51 compared to USD 0.60 a year ago. Excluding the impact of milestone revenue, net income and diluted EPS increased USD 1.6 million, and USD 0.11, respectively. For the six months, the company reported total revenue of USD 38,423,885 compared to USD 60,284,947 a year ago. Income from operations was USD 17,933,149 compared to USD 39,073,281 a year ago. Income before income taxes was USD 17,980,779 compared to USD 39,079,683 a year ago. Net income was USD 11,335,114 compared to USD 24,332,603 a year ago. Diluted net income per share was USD 0.74 compared to USD 1.57 a year ago.

Anika Therapeutics Inc. to Report Q2, 2015 Results on Jul 29, 2015

Anika Therapeutics Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Jul 29, 2015

Anika Therapeutics Inc., Q2 2015 Earnings Call, Jul 30, 2015

Anika Therapeutics Inc., Q2 2015 Earnings Call, Jul 30, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANIK:US $36.04 USD +0.63

ANIK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
IRIDEX Corp $6.86 USD -0.02
STAAR Surgical Co $7.70 USD +0.25
View Industry Companies
 

Industry Analysis

ANIK

Industry Average

Valuation ANIK Industry Range
Price/Earnings 21.2x
Price/Sales 6.3x
Price/Book 2.8x
Price/Cash Flow 20.5x
TEV/Sales 4.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANIKA THERAPEUTICS INC, please visit www.anikatherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.